Table 3.
Outcomes of studies evaluating sentinel lymph node (SLN) dissection and radiotherapy
| Author (years) | Study type | SLN | Median follow-up (months) | Type of RT | 5‑year LRR (in %) | 5‑year DFS (in %) | 5‑year OS (in %) |
|---|---|---|---|---|---|---|---|
| SLN+ RT | |||||||
| ACOSOG Z0011 (2011) [2]a | P | 446 | 75.6 (62.4–84.0) | WBRT, High tangent, nodal RT | 1.6 | 83.9 | 92.5 |
| ACOSOG Z0011 (2017) [3]a | P | 446 | 111.6 (82.8–124.0) | WBRT, High tangent, nodal RT | NA | 80.2b | 86.3b |
| Setton (2011) [21] | R | 326 | 55.0 (1.0–158.0) | – | 98.0c,d | 95.0c | 91.0c |
| 302 | Supine or prone WBRT, High tangents, nodal RT | 99.0c,d | 96.0c | 92.0c | |||
| Yi (2013) [22] | R | 188 | 66.0 (14.4–134.4) | WBRT | NA | 95.7 | 94.3 |
| 121 | 64.8 (14.4–134.4) | NA | 99.0 | 95.9 | |||
| Wang (2014) [23] | R | 1269e | 73.0 (24.0–143.0) | Not specified | NA | NA | NA |
| 393 | 0.0 | 95.6 | 89.4 | ||||
| Morrow (2017) [8] | P | 663 | 29.0 (2.0–76.0) | Supine or prone WBRT, nodal RT | NA | 93.0 | 95.0 |
| 484 | 37.0 (12.0–75.0) | 1.0 | NA | NA | |||
| Kittaka (2018) [7] | P | 189 | 36.0 (10.0–64.0) | WBRT ± High tangent | 1.1f | 96.8f | NA |
| 183 | NA | NA | NA | ||||
| Jung (2019) [24] | R | – | – | Not specified | NA | NA | NA |
| 707 | 1.1 | 97.7 | NA | ||||
| LISEN trialg | P | 131 | 44.0 (6.0–85.0) | WBRT | 1.5 | 93.6 | 96.9 |
SLN sentinel lymph node dissection, P prospective, R retrospective, RT radiotherapy, LRR locoregional recurrence, DFS disease-free survival, OS overall survival, WBRT whole breast radiotherapy, NA not available
aSLN group
b10 years
c4 years
dRegional control
eSLND + ALND
f3 years
gSLN + RT group